The combination of<unk>  is used to treat people with cystic fibrosis who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), the defective protein that causes the disease. This genetic abnormality is present in about half of cystic fibrosis cases in Canada. Its use is not recommended for anyone with cystic fibrosis in the United Kingdom as of 2018. While the medication resulted in improvement in the amount of air a person can breathe out in one second, the improvement seen did not reach a clinically important amount. The medication also does not appear to change a person's quality of life or the number of times a year a person has a worsening of lung function. Effects on life expectancy are unclear.
Lumacaftor/ivacaftor
Elexacaftor/tezacaftor/ivacaftor
Beclometasone/formoterol/glycopyrronium bromide
Mometasone/formoterol
Fluticasone/salmeterol
Beclometasone/formoterol
Lifitegrast
Ivacaftor